Trial Profile
Retrospective chart review of use of aflibercept in age-related macular degeneration patients previously treated with intravitreal bevacizumab or ranibizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2015
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Pharmacodynamics; Therapeutic Use
- 07 Dec 2015 New trial record